By supporting Peter Mac, you can help rapidly accelerate the pace of discovery and innovation to achieve transformational breakthroughs in cancer research, treatment, and patient care.
For other ways to donate, to make a pledge or request further information, please see below.
Please review our Privacy Policy for details about how we use and store your information.
Ways to donate
Donate online:
https://foundation.petermac.org/donate
Direct Deposit:
Bank: Commonwealth Bank of Australia
Account Name: Peter MacCallum Cancer Centre Foundation
BSB: 063012
Account: 1025 0293
Reference: Your full name
Cheque:
To “Peter MacCallum Cancer Foundation”
Locked Bag 5, A’Beckett Street, Melbourne Vic 8006
Phone: +61 412 339 901 – Sarah Hornby, Head of Philanthropy
Email:
*If you are a DGR 2 entity please fill in the contact form above and a team member will reach out to you
Philanthropy News
Carousel content with 5 slides.
![](/images/Foundation_/IG/Aparna_Rao_1.jpg)
Foundation funding drives melanoma research: Dr Aparna Rao
![](/images/Foundation_/Research_Images_/DJ3_2798_Preview_2K.jpg)
Foundation Grants awarded to 26 innovative new cancer research projects at Peter Mac
![](/images/Foundation_/News/ME010224SM114.jpeg)
Sam Docherty kicks in another $30K to support cancer research
![](/images/Gamma_Knife-min.jpeg)
Gamma Knife brings life-changing treatments to Peter Mac
![](/images/Foundation_/Research_Images_/Research_Image_Group.jpeg)
2022 Endowment Fund Grants: successful grant recipients
Our Speakers
Michael Milken
Chairman, Prostate Cancer Foundation (USA)
Mike Milken has been a driving force in medical research, education, public health, and access to capital for over five decades. Fortune dubbed him "The Man Who Changed Medicine" and Forbes recognised him among "Visionaries Reimagining Our Children’s Future."
Today, Mike is the Chairman of the Prostate Cancer Foundation, the largest private funder in its field, and serves as chairman of FasterCures, advancing progress against life-threatening diseases. He co-founded the Melanoma Research Alliance and contributed to establishing the Milken Institute School of Public Health at George Washington University, offering 30 degree options.
Professor Michael Hofman
Director, Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC)
Professor Hofman is a nuclear medicine physician, physician-scientist and Director of ProsTIC at Peter Mac. He was featured as the leading nuclear medicine researcher in the The Australian’s Top 250 Researchers 2024, and ranked number 1 globally by ExpertScape.
Professor Hofman led landmark research resulting in the global adoption of PSMA PET and PSMA radioligand therapy as new standards-of-care for imaging and targeted treatment for men with prostate cancer. His research contributed to FDA approval, MBS funding in Australia and a $2.1billion investment by Novartis in commercialisation.
He maintains a broad research interest in novel radiopharmaceuticals for imaging and therapy (theranostics) in oncology. Professor Hofman has active grants totalling more than $55 million dollars and he currently leads a US$10 million collaboration focused on development of 21st Century therapies for lethal forms of prostate cancer.
Philanthropy News
Carousel content with 5 slides.
![](/images/Foundation_/News/Lavinia_and_Minson.png#joomlaImage://local-images/Foundation_/News/Lavinia_and_Minson.png?width=776&height=472)
Two clinical researchers awarded 2024 Discovery Partner Fellowships
![](/images/Foundation_/Case studies/Lewis Au/IMG_5836.jpg#joomlaImage://local-images/Foundation_/Case studies/Lewis Au/IMG_5836.jpg?width=5472&height=3648)
Unlocking the secrets of kidney cancer
![](/images/Foundation_/IG/Aparna_Rao_1.jpg)
Foundation funding drives melanoma research: Dr Aparna Rao
Breakthroughs for bowel cancer: with Dr Oliver Piercey
![](/images/Gamma_Knife-min.jpeg)